Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An extended-release formulation of tenofovir, lamivudine and dolutegravir maintained effective drug levels for a month.
This year’s most widely viewed stories focused on HIV cure and vaccine news, long-acting treatment and coexisting conditions.
The clinical trial will evaluate once-weekly islatravir plus Sunlenca pills for people switching from a daily antiretroviral regimen.
An islatravir implant could potentially prevent HIV for several years, while an antiretroviral insert could offer on-demand protection.
90% of people who received an injection of lenacapavir plus two broadly neutralizing antibodies maintained viral suppression for six months.
The new injectable antiretroviral keeps HIV under control, but it still needs an equally long-acting partner.
Long-acting antiretrovirals are the future of HIV treatment, and new meds on the horizon could improve convenience and adherence.
The company will resume development of islatravir for HIV treatment but abandons monthly oral PrEP.
Islatravir, a long-acting antiretroviral, has hit a snag after clinical trial participants experienced falling white blood cell counts.
Studies of islatravir are put on hold after participants experience declining CD4 and lymphocyte counts.
COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year.
Awareness of the HIV prevention pills don’t match their use.
An islatravir PrEP implant could prevent HIV for a year.
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
Monthly islatravir pills are just one of the long-acting options in the HIV prevention pipeline.
Long-acting antiretrovirals were the big news at CROI this year; now two of the most promising are joining forces.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.